Abstract
Background
Fingerprints have long been used for personal identification; however, some case reports suggested that some chemotherapy agents such as paclitaxel lead to fingerprints loss due to hand-and-foot syndrome (HFS).
Methods
This case–control study was performed on 65 patients who received chemotherapy regimens with/without paclitaxel. Patients with the history of receiving any drugs with significant HFS adverse effect or patients with any conditions that affect fingerprints were excluded. Baseline and post-chemotherapy images of fingerprint examples were referred to the Iranian Society of Legal Medicine to compare changes in the fingerprints.
Results
Thirty-one patients entered in the paclitaxel and 34 subjects in the control groups. Seventeen patients (54.8%) in the paclitaxel group experienced fingerprint changes, whereas no patient had fingerprint changes in the control group. By physical examination, no patients in the two groups experienced HFS. After adjusting for age, sex, occupation, and cancer type, there was a significant difference between the two groups regarding fingerprint changes (P = 0.002, OR 13.69, 95% CI 2.05 to infinite).
Conclusions
Considering that fingerprint recognition has been utilized in both government and civilian investigation, patients taking paclitaxel and centers necessitating fingerprint identification should be informed about possible fingerprint changes by paclitaxel.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Ahwal MS (2012) Chemotherapy and fingerprint loss: beyond cosmetic. Oncologist 17(2):291–293. doi:10.1634/theoncologist.2011-0243
Assi HA, Ayoub ZA, Jaber SM, Sibai HA, El Saghir NS (2013) Management of paclitaxel-induced hand-foot syndrome. Breast Care (Basel) 8(3):215–217. doi:10.1159/000352097
Azadeh P, Yaghobi Joybari A, Amini A, Farasatinasab M (2014) Paclitaxel-Induced Fingerprints Loss. Ann Pharmacother 48(9):1249–1250. doi:10.1177/1060028014539145
Bardale R (2011) Principles of forensic medicine and toxicology. Jaypee Brothers Medical Publishers (P) Ltd, New Delhi
Blum JL, Jones SE, Buzder AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B et al (1999) Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol 17(2):485
Cadd S, Islam M, Manson P, Bleay S (2015) Fingerprint composition and aging: a literature review. Sci Justice 55(4):219–223
Chavarri-Guerra Y, Soto-Perez-de-Celis E (2015) Loss of fingerprints. N Engl J Med 327(16):e22. doi:10.1056/NEJMicm1409635
Chirillo J, Blsul S (2003) Implementing biometric security. Wiley, Hoboken. ISBN 978-0-7645-2502-6
Common terminology criteria for adverse events, version 4.03, June 2010, National Institutes of Health, National Cancer Institute, file:http//www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Cruz A, Temu T, Hines-Telang G, Kroumpouzos G (2011) Paclitaxel-induced neutrophilic adverse reaction and acral erythema. Acta Derm Venereol 91:86–87
De Arila D, Dominguez JD, Iglesias L (1996) Taxol-induced acral erythema. Dermatology 192:377–378
Drahansky M, Dolezel M, Urbanek J, Brezinova E, Kim TH (2012) Influence of skin diseases on fingerprint recognition. J Biomed Biotechnol 2012:626148
Flory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB (1999) Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 33(5):584–586
Garcia-Saenz JA, Martin M, Diaz-Rubio E (2007) Elementary, my dear Watson. J Clin Oncol 25(13):1815–1816
Girod A, Ramotowski R, Weyermann C (2012) Composition of fingermark residue: a qualitative and quantitative review. Forensic Sci Int 223(1):10–24
Hirji KF (2005) Exact analysis of discrete data. Chapman and Hall/CRC Press, Boca Raton, FL
Haber R, Helou J, Korkomaz J, Habre M, Ghanem A, Tomb R (2015) Absence of fingertips with focus on dermatological etiologies: national survey and review. Clin Dermatol 3(1):21–26
Hueso L, Sanmartín O, Nagore E, Botella- Estrada R, Requena C, Llombart B, Serra- Guillén C, Alfaro-Rubio A, Guillén C (2008) Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases. Actas Dermosifiliogr 99:281–290
Jain AK, Flynn P, Ross AA (2008) Handbook of biometrics. Springer, Berlin. ISBN 978-0-387-71040-2
Lacy CF, Armstrong LL, Goldman MP, Lance LL (eds) (2011) Drug information handbook, 20th edn. Lexi-Comp, Hudson
Lassere Y, Hoff P (2004) Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8(Suppl 1):S31–S40
Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B et al (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16(9):2977–2985
Payne JY, Holmes F, Cohen PR, Gagel R, Buzdar A, Dhingra K (1996) Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. South Med J 89:542–545
R Core Team (2014) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. http://www.R-project.org/
Roh MR, Cho JY, Lew W (2007) Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. Yonsei Med J 48(1):124–126
Sergeant A, McPhee N, Holme SA (2012) Acquired loss of fingerprints: do topical corticosteroids play an aetiological role? Clin Exp Dermatol 37(6):679–680. doi:10.1111/j.1365-2230.2011.04307.x
Wong M, Choo SP, Tan EH (2009) Travel warning with capecitabine. Ann Oncol 20(7):1281. doi:10.1093/annonc/mdp278
Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592–596
Yarbro CH, Frogge MH, Goodman M (eds) (2004) Cancer symptom management, 3rd edn. Jones and Bartlett Publishers, Sudbury
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Additional information
Institution where the work was performed: Imam Hussein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rights and permissions
About this article
Cite this article
Azadeh, P., Dashti-Khavidaki, S., Joybari, A.Y. et al. Fingerprint changes among cancer patients treated with paclitaxel. J Cancer Res Clin Oncol 143, 693–701 (2017). https://doi.org/10.1007/s00432-016-2314-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2314-1